Eloxx Pharmaceuticals, Inc.
ELOX
|
$1.02
-51.57%
93K
|
Health Technology
(0.0% 1d) (13.3% 1m) (-86.9% 1y) (4.1% 2d) (1.0% 3d) (-1.9% 7d) (1451.63% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 3,206,258
http://www.eloxxpharma.com
Sec Filling | Patents | 29 employees
(US) Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Waltham, MA.
israel fibrosis molecule drugs
add to watch list Paper trade email alert is off
Press-releases
Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival; Nubia Brand International Corp.; The Alkaline Water Company Inc.; DMK Pharmaceuticals Corporation; MedAvail Holdings, Inc.; InVivo Therapeutics Holdings Corp.; and ADDvantage Technologies Group, Inc. from The Nasdaq Stock Market
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
COMS | $0.2 37.35% 2.2K
|
Manufacturing
|
| O: -2.27%
H: 27.46%
C: 15.87%
WTER | $0.0015 14185.71% 800
|
Consumer Non-Durables
|
| O: 0.0%
H: 614.29%
C: 0.0%
NDAQ | $60.2 -2.15% -2.19% 3.2M
|
Finance
|
| O: 0.46%
H: 3.09%
C: 1.11%
CETX | $3.34 -3.24% 5.7K
|
Electronic Technology
|
| O: 0.22%
H: 1.85%
C: -2.22%
water company international spac pharmaceuticals global system medical therapeutics market
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Published: 2024-03-13 (Crawled : 16:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
| Email alert
Add to watchlist
zkn-013 rare license pharmaceuticals dermatological agreement
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
| Email alert
Add to watchlist
business update pharmaceuticals financial results
Emerging Market Trends in Muscular Dystrophy: A DelveInsight Analysis of Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-girdle Muscular Dystrophy
Published: 2023-11-06 (Crawled : 22:00) - prnewswire.com
SRPT | $118.385 -3.65% -3.79% 770K
|
Health Technology
|
| O: 0.65%
H: 4.43%
C: 2.87%
RNA | $23.91 -0.75% -0.75% 870K
|
Health Technology
|
| O: -0.57%
H: 10.72%
C: 10.63%
trends market
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Published: 2023-10-09 (Crawled : 12:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
|
| O: -0.46%
H: 4.19%
C: 2.33%
elx-02 kidney pharmaceuticals study
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-09-19 (Crawled : 12:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
|
| O: -0.18%
H: 1.83%
C: 1.83%
nasdaq direct offering pharmaceuticals
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
|
| O: 1.87%
H: 0.0%
C: -8.85%
elx-02 positive pharmaceuticals results study
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
|
| O: 7.22%
H: 0.0%
C: -5.14%
elx-02 zkn-013 pharmaceuticals program
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-08-14 (Crawled : 12:20) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
|
| O: 5.05%
H: 20.04%
C: 14.83%
business update pharmaceuticals financial results
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
ELOX | $1.02 -51.57% 93K
|
Health Technology
|
| O: 5.05%
H: 20.04%
C: 14.83%
elx-02 drug pharmaceuticals response study phase 2
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10